Treatment patterns, healthcare resource utilization and outcomes for early stage triple-negative breast cancer in Japan-Reference-Cited by-同舟云学术

Treatment patterns, healthcare resource utilization and outcomes for early stage triple-negative breast cancer in Japan

Published:2024-04 Issue:13 Volume:20 Page:833-849
ISSN:1479-6694
Container-title:Future Oncology
language:en
Short-container-title:Future Oncol.

Author:

Sanno Hitomi¹^ORCID,Taniguchi Kazuko¹^ORCID,Yoshimoto Yuya²^ORCID,Saji Shigehira³^ORCID

Affiliation:

1. MSD K.K., Tokyo, Kitanomaru Square, 1-13-12 Kudan-kita, Chiyoda-ku, Tokyo, 102-8667, Japan

2. Department of Radiation Oncology, School of Medicine, Fukushima Medical University, 1 Hikarigaoka, Fukushima, 960-1295, Japan

3. Department of Medical Oncology, School of Medicine, Fukushima Medical University, 1 Hikarigaoka, Fukushima, 960-1295, Japan

Funder

Merck Sharp and Dohme K.K.

Publisher

Informa UK Limited

Link

https://www.tandfonline.com/doi/pdf/10.2217/fon-2023-0960

Reference20 articles.

1. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries

2. National Cancer Institute Cancer Information Service . Statistics by Cancer Species—Breast. (In Japanese). https://ganjoho.jp/reg_stat/statistics/stat/cancer/14_breast.html#anchor3 (Accessed 30January2023).

3. Japanese Breast Cancer Society . Breast Cancer Clinical Practice Guidelines 2022. (In Japanese). https://jbcs.xsrv.jp/guideline/2022/ (Accessed 30January2023).

4. Lymph node metastasis and high serum CEA are important prognostic factors in hormone receptor positive and HER2 negative breast cancer;Kosaka Y;Mol Clin Oncol.,2018

5. Patient survival and healthcare utilization costs after diagnosis of triple-negative breast cancer in a United States managed care cancer registry